Skip to Content

Alogliptin / pioglitazone Pregnancy and Breastfeeding Warnings

Alogliptin / pioglitazone is also known as: Oseni

Alogliptin / pioglitazone Pregnancy Warnings

Alogliptin: Not teratogenic when administered to animals during organogenesis. In addition, no harm to the developing embryo or adverse effects on the growth and development of offspring was observed when given to animals at approximately 95 times the clinical exposure. Following oral administration to pregnant animals, placental transfer of was observed. Animal fertility studies showed no adverse effects on embryonic development, mating, or fertility at doses approximately 172 times the clinical dose. Pioglitazone: Animal studies have not revealed evidence of teratogenicity. Increases in embryotoxicity (postimplantation losses, delayed development, reduced fetal weights, and delayed parturition) were observed in animals. When administered to pregnant animals during late gestation and lactation, delayed postnatal development (attributed to decreased body weight) occurred. There are no controlled data in human pregnancy. US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D, and X are being phased out.

Potential benefit should outweigh the potential risk. FDA pregnancy category: Not assigned Risk summary: Abnormal blood glucose concentrations during pregnancy are associated with a higher incidence of congenital anomalies, increased neonatal morbidity, and mortality. Most experts recommend insulin use during pregnancy to maintain blood glucose concentrations as close to normal as possible. Comment: Premenopausal anovulatory women may be at risk for pregnancy with use of pioglitazone; these women should be informed of pregnancy risk.

See references

Alogliptin / pioglitazone Breastfeeding Warnings

A decision should be made to discontinue breast-feeding or discontinue the drug, taking into account the importance of the drug to the mother. Excreted into human milk: Unknown (alogliptin and pioglitazone) Excreted into animal milk: Yes (alogliptin and pioglitazone) The effects in the nursing infant are unknown.

See references

References for pregnancy information

  1. "Product Information. Oseni (alogliptin-pioglitazone)." Takeda Pharmaceuticals America, Lincolnshire, IL.

References for breastfeeding information

  1. "Product Information. Oseni (alogliptin-pioglitazone)." Takeda Pharmaceuticals America, Lincolnshire, IL.

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.